[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620644":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":44,"centralContacts":48,"locations":54,"responsibleParty":68,"collaborators":70,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":37,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":37,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":37,"overallStatus":93,"whyStopped":37,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University of Wisconsin, Madison","OTHER",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Psilocybin While Awake, Placebo While Asleep","EXPERIMENTAL","Participants in this group will receive psilocybin by intravenous (IV) infusion while awake and placebo (saline) by IV infusion while asleep during an overnight dosing visit. All participants will also receive oral clonidine prior to dosing to support sleep during the overnight visit.",[13,14,15],"Drug: Psilocybin","Other: Saline Placebo","Drug: Clonidine",{"label":17,"type":10,"description":18,"interventionNames":19},"Placebo While Awake, Psilocybin While Asleep","Participants in this group will receive placebo (saline) by intravenous (IV) infusion while awake and psilocybin by IV infusion while asleep during an overnight dosing visit. All participants will also receive oral clonidine prior to dosing to support sleep during the overnight visit.",[13,14,15],{"label":21,"type":22,"description":23,"interventionNames":24},"Placebo While Awake, Placebo While Asleep","PLACEBO_COMPARATOR","Participants in this group will receive placebo (saline) by intravenous (IV) infusion while awake and placebo by IV infusion while asleep during an overnight dosing visit. All participants will also receive oral clonidine prior to dosing to support sleep during the overnight visit.",[14,15],[26,33,38],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Psilocybin","IV administration, infusion of 3.2 mg psilocybin over 10 minutes, followed by an additional 0.8 mg infused over the following 20 minutes",[17,9],[32],"intravenous psilocybin",{"type":6,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"Saline Placebo","IV administration, placebo will be 20 mL of saline drawn up aseptically into the same sized (30 mL) syringe as is used for the active drug.",[21,17,9],null,{"type":27,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Clonidine","0.2 mg of clonidine will be taken by mouth by all participants 60 minutes prior to the initial infusion on Dosing Night",[21,17,9],[43],"Clonidine ER",[45],{"name":46,"affiliation":5,"role":47},"Charles Raison, MD","PRINCIPAL_INVESTIGATOR",[49],{"name":50,"role":51,"phone":52,"phoneExt":37,"email":53},"CoPEWell Study Contact","CONTACT","608-263-4852","copewell@psychiatry.wisc.edu",[55],{"facility":56,"status":37,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":37},"University of Wisconsin","Madison","Wisconsin","53792","United States","US",{"type":63,"coordinates":64},"Point",[65,66],-89.40123,43.07305,{"lat":66,"lon":65},{"type":69,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR",[71],{"name":72,"class":6},"Tiny Blue Dot Foundation","100620644","phase-1-consciousness-and-psilocybin-effects-on-well-being-the-copewell-study-100620644",false,"NCT07360301","Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study","Inclusion Criteria:\n\n* Age 18 to 45 years (inclusive) at screening, of any identified gender and racial\u002Fethnic group\n* Physically healthy; does not meet criteria for an exclusionary medical condition\n* No exclusionary sleep condition\n* English-speaking (able to provide consent and complete questionnaires)\n* Sub-optimal self-reported wellbeing\n\nExclusion Criteria:\n\n* Exclusionary DSM-5 psychiatric diagnosis and\u002For active suicidal ideation\n* Exclusionary medical conditions or sleep conditions\n* Clinically significant safety lab abnormalities (i.e., Complete Blood Count with Differential, Comprehensive Metabolic Panel, and urinalysis)\n* Clinically significant electrocardiogram (ECG)\n* Use of psychotropic or CNS-altering medications within 3 months of screening\n* Hypertension or tachycardia",true,"ALL","18 Years","45 Years",{"count":84,"type":85},120,"ESTIMATED","INTERVENTIONAL",[88],"PHASE1","This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why. The CoPEWell study will test whether these improvements come from the psychedelic experience itself (the \"trip\") or from direct effects on the brain. To study this, up to 120 participants will be enrolled to receive psilocybin either while awake or asleep and can expect to be on study for up to 4 months.",[91,92],"Well-Being, Psychological","Psychedelic Experiences","NOT_YET_RECRUITING","2026-06-30",{"date":96,"type":97},"2026-07-02","ACTUAL",{"date":99,"type":85},"2026-09",{"date":101,"type":85},"2028-02",{"name":5,"class":6},1]